Munich Reinsurance Co Stock Corp in Munich Makes New $6.75 Million Investment in Zoetis Inc. $ZTS

Munich Reinsurance Co Stock Corp in Munich bought a new position in shares of Zoetis Inc. (NYSE:ZTS) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 46,122 shares of the company’s stock, valued at approximately $6,749,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Halbert Hargrove Global Advisors LLC grew its position in shares of Zoetis by 496.6% during the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after buying an additional 144 shares in the last quarter. Financial Consulate Inc. purchased a new position in Zoetis in the third quarter valued at $39,000. SJS Investment Consulting Inc. raised its stake in Zoetis by 1,606.3% in the third quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock valued at $40,000 after buying an additional 257 shares in the last quarter. TruNorth Capital Management LLC acquired a new position in shares of Zoetis during the 3rd quarter worth about $42,000. Finally, Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Zoetis during the 3rd quarter worth about $46,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Price Performance

Zoetis stock opened at $121.54 on Friday. Zoetis Inc. has a 52-week low of $115.25 and a 52-week high of $177.00. The firm has a market capitalization of $51.31 billion, a P/E ratio of 20.19, a PEG ratio of 1.85 and a beta of 0.95. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The firm has a fifty day moving average of $126.06 and a 200-day moving average of $133.05.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. The company had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be given a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s payout ratio is presently 35.22%.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. William Blair reiterated an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Stifel Nicolaus dropped their target price on Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a report on Tuesday, November 18th. Piper Sandler reiterated a “neutral” rating and issued a $135.00 price objective (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. HSBC set a $140.00 target price on Zoetis in a research report on Wednesday, December 10th. Finally, Bank of America lifted their price target on shares of Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research report on Friday, February 13th. Six equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $152.91.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.